BridgeMD
New treatment option for Breast Cancer-Related Lymphedema
Official title Comparison of IPC Therapy as an Alternative or an Adjunct to MLD Within CDT for BCRL
ClinicalTrials.gov ID: NCT07154043
What this study is testing
- What it's testing
- Breast cancer is the most common cancer among women worldwide and lymphedema is one of its most significant complications. Breast cancer-related lymphedema (BCRL) may develop shortly after treatment or even years later, causing physical and psychological burden, functional impairment, and reduced quality of life.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65, women only
You may be able to join if
- Female gender
- Patients aged 18-65 years
- Having a history of unilateral mastectomy and lymph node dissection at least one year ago due to breast cancer diagnosis.
- Having unilateral breast cancer-related upper extremity lymphedema (\>20% volume difference between the two upper extremities or \>2 cm difference in...
- Not having received lymphedema treatment or exercise therapy for the last six months
You likely can't join if
- Bilateral breast cancer
- Bilateral axillary lymph node dissection
- Metastatic breast cancer
- Receiving ongoing radiotherapy or chemotherapy
- Primary or bilateral lymphedema
- Having active cancer
See the full eligibility criteria
- Female gender
- Patients aged 18-65 years
- Having a history of unilateral mastectomy and lymph node dissection at least one year ago due to breast cancer diagnosis.
- Having unilateral breast cancer-related upper extremity lymphedema (\>20% volume difference between the two upper extremities or \>2 cm difference in circumference at any measured point) according to the diagnostic...
- Not having received lymphedema treatment or exercise therapy for the last six months
- Completing breast cancer primary treatment at least 6 months ago (except hormone therapy/aromatase inhibitors)
- Bilateral breast cancer
- Bilateral axillary lymph node dissection
- Metastatic breast cancer
- Receiving ongoing radiotherapy or chemotherapy
- Primary or bilateral lymphedema
- Having active cancer
- Presence of stage 3 lymphedema
- Uncontrolled serious systemic disease (cardiopulmonary diseases, arterial or venous diseases, renal dysfunction, uncontrolled hypertension or hypotension, cardiac arrhythmia, scleroderma, Sudek's atrophy).
- Current or recent (within the last 3 months) infection (cellulitis, lymphangitis) or deep venous thrombosis
- Presence of open wounds
- Using medications that may affect body fluid and electrolyte balance (diuretics, etc.).
- Individuals with serious mental and sensory problems
- Being pregnant
- Body mass index \>40 kg/m2
The study team makes the final eligibility decision.
Where it's taking place
- Denizli, Turkey (Türkiye)
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Denizli, Turkey (Türkiye). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.